Maze Therapeutics, Inc.
MAZE
$27.18
-$0.49-1.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.56% | 18.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.18% | 22.32% | |||
| Operating Income | -80.90% | 30.23% | |||
| Income Before Tax | -84.76% | 29.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -84.76% | 29.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -84.76% | 29.97% | |||
| EBIT | -80.90% | 30.23% | |||
| EBITDA | -82.48% | 30.49% | |||
| EPS Basic | -68.77% | 30.61% | |||
| Normalized Basic EPS | -68.79% | 30.62% | |||
| EPS Diluted | -69.19% | 30.61% | |||
| Normalized Diluted EPS | -68.79% | 30.62% | |||
| Average Basic Shares Outstanding | 9.46% | 0.94% | |||
| Average Diluted Shares Outstanding | 9.46% | 0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||